Radiologia Brasileira - Publicação Científica Oficial do Colégio Brasileiro de Radiologia

INTRODUCTION

Primary bone lymphoma (PBL) is a rare disease, accounting for only 3–7% of all primary bone neoplasms, approximately 5% of extranodal lymphomas, and less than 1% of all non-Hodgkin lymphomas^(1,2), diffuse large B-cell lymphoma being the most common^(1–4). They are extremely rare in the pediatric and young adult populations⁽²⁾.

The following criteria for the diagnosis of PBL are widely accepted⁽¹⁾: the primary site of tumor origin being in the bone marrow, no other site indicating the existence of the lesion on physical or imaging examination; no lymphoma being identified at any other site within the first six months after the diagnosis of PBL; the diagnosis being confirmed by pathology and immunohistochemistry; a diagnosis of malignant lymphoma, with the exception of PBL and secondary bone lymphoma, having been excluded.

Lymphomatous involvement of bone occurs most often in the metadiaphysis⁽¹⁾, the femur being the most affected site, followed by the tibia and humerus⁽⁵⁾, although there is considerable divergence in the literature between appendicular and axial involvement, especially in studies conducted in Japan^(3,6). Other sites of involvement include the pelvis, skull, and neck^(3,7). Multifocal lesions usually affect axial and appendicular bones⁽⁵⁾.

In most studies, PBL is diagnosed in patients between 50 and 70 years of age, primarily affecting males⁽³⁾. Clinically, PBL manifests as local pain, a palpable mass, or pathological fracture, and some patients develop B symptoms (fever, night sweats, and weight loss).

The clinical presentation and imaging findings of PBL, which will be discussed below, are nonspecific, with a wide range of possible differential diagnoses, including Ewing’s sarcoma, osteosarcoma, chondrosarcoma, metastases, and Langerhans cell histiocytosis⁽²⁾. However, the thorough evaluation of specific radiological patterns can increase the level of suspicion for PBL before tissue biopsy.

The objective of this pictorial essay is to illustrate the most frequent findings obtained with the various imaging methods used in patients with PBL.


GENERAL IMAGING CHARACTERISTICS

Originating from the bone marrow, PBL is a neoplasm that has widely variable presentations on imaging, and the findings can overlap with those numerous non-neoplastic conditions, as well as with those of other benign or malignant neoplasms. One common, striking feature is a soft-tissue mass that is much larger than would be expected on the basis of the degree of cortical bone destruction. In other words, a mass that extends to soft tissues with relative preservation of the cortical bone may be typical of PBL^(4,7). It has been suggested that this pattern results from the spread of small, round, blue tumor cells throughout the cortical bone via Volkmann’s and Havers’ vascular canals to the surrounding soft tissues, rather than from a clear cortical break^(4,7).


RADIOGRAPHY

Conventional X-ray is used in the initial assessment of the clinical complaint and can reveal aspects that merit further investigation. In this clinical context, the radiological appearance of a bone lymphoma can be normal or can include mild textural changes in the bone marrow⁽¹⁾, as shown in Figure 1.




Most reports of PBL describe an osteolytic pattern of infiltrative bone destruction with a wide transition zone or a moth-eaten appearance (Figure 2), and a periosteal reaction commonly reported to have a lamellar, multilamellar (“onion skin”), or discontinuous aspect⁽¹⁾.




ULTRASOUND

Ultrasound has limited specificity to diagnose and differentiate PBL lesions. Its main function is to guide puncture or percutaneous biopsy of bone tumors that are accompanied by an extraosseous soft-tissue mass (Figure 3). Ultrasound can be used as an adjunct to magnetic resonance imaging (MRI) when secondary susceptibility artifacts prevent the assessment of specific areas⁽⁸⁾.




COMPUTED TOMOGRAPHY

Computed tomography (CT), in addition to being a widely used method to guide biopsies in cases of bone tumors (Figure 4), is an excellent method for delineating cortical destruction. Even if the other characteristics identified are nonspecific, the diagnosis of PBL should be considered whenever a large soft-tissue mass and abnormal bone marrow attenuation are observed without extensive cortical destruction proportional to the volume of the extraosseous lesion⁽⁹⁾.




BONE SCINTIGRAPHY

Although radionuclide bone scintigraphy (^99mTc scintigraphy) is usually nonspecific, it helps to detect any active area in the skeleton, determining whether a tumor is latent or active⁽⁷⁾. Increased uptake of the tracer is seen in 98% of patients with PBL, that uptake (activity) being markedly increased in 64%^(7,10).


POSITRON EMISSION TOMOGRAPHY/CT

Positron emission tomography/CT (PET/CT) shows greater specificity and sensitivity than does conventional bone scintigraphy in the identification of lymphomatous infiltration of the skeleton⁽¹⁾. In most cases, PBL presents as a hypermetabolic lesion on examination with fluorodeoxyglucose (Figure 5). In the follow-up of patients with PBL, PET/CT is an important tool to assess the presence of a viable lesion, being used even to define the therapeutic response. Post-therapeutic changes, such as tumor necrosis, granulation tissue, and fibrosis, are often difficult to distinguish from tumor remnants on CT and MRI. In this context, the presence or absence of uptake of the radiotracer in a PET/CT examination helps define more precisely the nature of the remaining tissue.




MRI

Because it provides excellent soft-tissue contrast between compartments, MRI demonstrates well the relationship with neurovascular structures and shows the extent to which a lesion has invaded bone marrow, as well as the size and volume of the lesion. It allows tissue characterization by assessing signal intensities with different pulse sequences, the characteristics of contrast enhancement and the intensity of restricted diffusion on diffusion-weighted imaging⁽⁴⁾.

In patients with PBL, T1-weighted MRI sequences show areas of low signal intensity, and are generally the best sequences for revealing changes in bone marrow content. In contrast, those same areas show an intermediate signal on T2-weighted sequences (Figure 6). Peritumoral edema and reactive bone marrow changes can produce high signal intensity that varies depending on the degree of fibrosis^(1,4). Exhibiting varying degrees of contrast enhancement, PBLs, because of their relatively high cellularity, show restricted diffusion with a low apparent diffusion coefficient on diffusion-weighted sequences⁽¹⁾. Finally, MRI is the best imaging method to assess the extent of bone injury in the soft-tissue compartments and the degree of cortical involvement in PBL, the cortical bone typically being preserved because of the infiltrative pattern of cortical penetration⁽⁹⁾, as depicted in Figure 7.






CONCLUSION

Although PBL is a rare entity and its final diagnosis is carried out through pathological and immunohistochemical analysis, radiological evaluation is important for early diagnosis in incidental discoveries, biopsy guidance, staging, and evaluation of locoregional involvement, as well as follow-up and response assessment. Because there are no specific image characteristics, clinical, epidemiological, evolutionary and imaging knowledge helps guide the differential diagnosis of PBL, and for that we have an arsenal of imaging modalities that radiologists and general practitioners should be aware of, not only in terms of their interpretation but also in terms of the most appropriate indications for each modality.


REFERENCES

1. Messina C, Christie D, Zucca E, et al. Primary and secondary bone lymphomas. Cancer Treat Rev. 2015;41:235–46.

2. Elhassadi E. Primary lymphoma of bone literature review. J Orthop Oncol. 2017;3:1000119.

3. Matikas A, Briasoulis A, Tzannou I, et al. Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center. Acta Haematol. 2013;130:291–6.

4. Caracciolo JT, Rose T, Bui MM. Primary lymphoma of bone: imaging findings to improve diagnosis of a rarely considered disease prior to biopsy. Open Journal of Clinical Diagnostics. 2015;5:97–106.

5. Lim CY, Ong KO. Imaging of musculoskeletal lymphoma. Cancer Imaging. 2013;13:448–57.

6. Maruyama D, Watanabe T, Beppu Y, et al. Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol. 2007;37:216–23.

7. Coley BL, Higinbotham NL, Groesbeck HP. Primary reticulum-cell sarcoma of bone; summary of 37 cases. Radiology. 1950;55:641–58.

8. Van der Woude HJ, Vanderschueren G. Ultrasound in musculoskeletal tumors with emphasis on its role in tumor follow-up. Radiol Clin North Am. 1999;37:753–66.

9. Weber MA, Papakonstantinou O, Nikodinovska VV, et al. Ewing’s sarcoma and primary osseous lymphoma: spectrum of imaging appearances. Semin Musculoskelet Radiol. 2019;23:36–57.

10. Zhou HY, Gao F, Bu B, et al. Primary bone lymphoma: a case report and review of the literature. Oncol Lett. 2014; 8:1551–6.










1. Department of Imaging, A.C.Camargo Cancer Center, São Paulo, SP, Brazil

a. https://orcid.org/0000-0002-0738-177X
b. https://orcid.org/0000-0002-8079-0123
c. https://orcid.org/0000-0002-4124-8032
d. https://orcid.org/0000-0003-0192-9885
e. https://orcid.org/0000-0003-0203-6376

Correspondence:
Dr. Wagner Santana Cerqueira
A.C.Camargo Cancer Center – Departamento de Imagem
Rua Professor Antônio Prudente, 211, Liberdade. São Paulo, SP, Brazil, 01509-010
Email:wagner_scerqueira@yahoo.com.br

Received 9 December 2019
Accepted after revision 5 February 2020